tiprankstipranks
Cytokinetics (CYTK)
NASDAQ:CYTK

Cytokinetics (CYTK) Income Statement

929 Followers

Cytokinetics Income Statement

Last quarter (Q4 2023), Cytokinetics's total revenue was $1.67M, a decrease of -14.56% from the same quarter last year. In Q4, Cytokinetics's net income was $-136.90M. See Cytokinetics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 7.53M$ 7.53M$ 94.59M$ 70.43M$ 55.83M$ 26.87M
Cost of Revenue
----$ 96.95M-
Gross Profit
$ 7.53M$ 7.53M$ -146.22M$ 70.43M$ -41.12M-
Operating Expense
$ 503.74M$ 503.74M$ -177.98M$ 256.74M$ 52.82M$ 125.73M
Operating Income
$ -496.20M$ -496.20M$ -324.20M$ -186.31M$ -93.94M$ -98.87M
Net Non Operating Interest Income Expense
$ -21.88M$ -28.31M$ -39.81M$ -16.11M$ -33.35M$ -22.82M
Other Income Expense
$ -21.20M$ -27.63M$ 24.94M$ -2.84M--
Pretax Income
$ -496.88M$ -496.88M$ -388.95M$ -202.42M$ -127.29M$ -121.69M
Tax Provision
----$ 0.00-
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -526.24M$ -526.24M$ -388.95M$ -215.31M$ -127.29M$ -121.69M
Basic EPS
$ -1.39K$ -5.45$ -4.33$ -2.80$ -1.97$ -2.11
Diluted EPS
$ -1.39K$ -5.45$ -4.33$ -2.80$ -1.97$ -2.11
Basic Average Shares
$ 386.10K$ 96.52K$ 89.83K$ 76.89K$ 64.52M$ 57.58M
Diluted Average Shares
$ 386.10K$ 96.52K$ 89.83K$ 76.89K$ 64.52M$ 57.58M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 503.74M$ 503.74M$ 418.79M$ 256.74M$ 149.77M$ 125.73M
Net Income From Continuing And Discontinued Operation
$ -526.24M$ -526.24M$ -388.95M$ -215.31M$ -127.29M$ -121.69M
Normalized Income
$ -293.78M$ -392.54M$ -262.50M-$ -127.29M$ -121.69M
Interest Expense
----$ 38.68M$ 27.36M
EBIT
$ -468.58M$ -468.58M$ -312.86M$ -185.98M$ -88.61M$ -94.33M
EBITDA
$ -355.11M$ -472.42M$ -311.76M$ -178.81M$ -86.78M$ -93.04M
Currency in USD

Cytokinetics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis